| Virbac | |
|--|--|
| Financial Details | |
| Total Company Revenue in 2010 | \$ 0.781 Bn |
| Revenue from Animal Health Market in 2010 | \$ 0.781 Bn |
| % of revenue from Animal Health in 2010 | 100% (The company is only into Animal Health) |
| Segmentwise Revenue Breakup (\$ Bn) | |
| Livestock Vaccines | 0.294 |
| Companion Vaccines | 0.469 |
| Number of Major Vaccines (Animal-wise) | |
| Poultry | 0 |
| Swine | 0 |
| Fish | 0 |
| Sheep | 0 |
| Cattle | 0 |
| Canine | 6 |
| Feline | 2 |
| Equine | 0 |
| Mergers and Acquisitions (2009 - 2011) | Consideration |
| Santa Elena laboratory | \$ 3.7 Mn |
| Veterinary Assets from Pfizer Inc. | undisclosed |
| Future Focus Areas | |
| Veterinary Vaccines under trial | 0 |
| Future Focus Areas of the company in the Veterinary Vaccines Market | Bacterian and virus vaccines |
| | Parasiticides and vaccines for cattle and sheep |

Go back to homepage